Below are summaries of recently published analyses from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Click on the shortened citations to access the publications.

Breast Cancer – There is limited information on quality of life for patients with ductal carcinoma in situ (DCIS), a non-life-threatening stage 0 breast cancer. This analysis reveals factors linked to declining mental health in the 2 years after surgery, based on data from the treatment trial E4112. Quality of Life Among Patients With Ductal Carcinoma In Situ. Dunsmore VJ. JAMA Netw Open. July 2025

Leukemia – This laboratory study is from the practice-changing E1910 trial. Multipotent Lineage Potential in B Cell Acute Lymphoblastic Leukemia is Associated with Distinct Cellular Origins and Clinical Features. Iacobucci I. Nature Cancer. June 2025

NCI-MATCH – Arm Z1K met its primary endpoint, showing clinically significant activity in patients with various tumors harboring AKT1^E17K mutations. Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K. McCourt CK. Clin Cancer Res. July 2025

NCI-MATCH – This examination found that different next-generation sequencing tests currently in widespread clinical use for tumor profiling achieved high concordance in variant detection. A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial. Zane LK. Clin Cancer Res. July 2025

NCI-MATCH –  As liquid biopsies with circulating tumor DNA (ctDNA) are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in cancer, this study looks at the correlation between plasma DNA analysis and tumor tissue–based sequencing. Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Gouda MA. Clin Cancer Res. June 2025

Penile Cancer – The InPACT trial (EA8134) aims to determine the optimal sequencing of management of surgery, chemotherapy, and chemoradiotherapy for patients with locally advanced penile cancer. Radiation therapy guidelines established at trial inception are now published to provide guidance for clinicians managing a rare clinical scenario. Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT). Cooper S. Int J Radiat Oncol Biol Phys. September 2025

Prostate Cancer – An artificial intelligence (AI) tool was able to interpret images of samples of prostate cancer tissue in a group of men with metastatic prostate cancer and identify those at higher risk of worse outcomes. The study used data from the CHAARTED (E3805) trial. Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer. Markowski MC. Eur Urol Oncol. June 2025

Prostate Cancer – Alterations in the PTEN tumor suppressor gene are common in prostate cancer and are known to be linked with more aggressive disease, poor outcomes, and the potential to benefit from targeted therapy. However, this biomarker study used data from the CHAARTED (E3805) trial to examine low PTEN mRNA expression as a unique profile. Clinical and Transcriptomic Characterization of Metastatic Hormone-Sensitive Prostate Cancer Patients with Low PTEN Expression. Garcia M. Int J Mol Sci. June 2025